Compare AstraZeneca plc (AZN) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Roundhill NVDA WeeklyPay ETF — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while Roundhill NVDA WeeklyPay ETF trades at $37.39. The key difference: AstraZeneca plc pays a 1.92% dividend while Roundhill NVDA WeeklyPay ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| AZN | NVDW | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $53.42 |
52-Week Low | $137.44 | $31.88 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
NVDW trades at $35.81, down 4.66% over the past day, with technical indicators showing mixed signals—bullish oscillators but bearish moving averages. The stock has a history of frequent dividend payments, with recent payouts ranging from $0.21 to $0.48 per share. Key support is near $35, while resistance levels start at $38.
The outlook hinges on NVDW's ability to maintain its dividend stream amid market volatility. Risks include dependency on underlying asset performance and payout fluctuations. Upside potential exists if technical resistance is broken, but investors should monitor earnings stability and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
